| Mohsen Ebneshahidi, MD | |
|
18460 Roscoe Blvd Fl 3, Northridge, CA 91325-4107 | |
| (818) 885-5480 | |
| (818) 993-1917 |
| Full Name | Mohsen Ebneshahidi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 22 Years |
| Location | 18460 Roscoe Blvd Fl 3, Northridge, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801168471 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | A121681 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northridge Hospital Medical Center | Northridge, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dignity Health Medical Foundation | 7810800661 | 1209 |
News Archive
CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.
› Verified 5 days ago
| Entity Name | Dignity Health Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700803418 PECOS PAC ID: 7810800661 Enrollment ID: O20031107000709 |
News Archive
CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.
› Verified 5 days ago
| Entity Name | Providence Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285890624 PECOS PAC ID: 8921993205 Enrollment ID: O20040216001346 |
News Archive
CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.
› Verified 5 days ago
| Entity Name | Inpatient Services Of California A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609019215 PECOS PAC ID: 3274421532 Enrollment ID: O20040413000789 |
News Archive
CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.
› Verified 5 days ago
| Entity Name | Inpatient Services Of California A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609019215 PECOS PAC ID: 3274421532 Enrollment ID: O20040601001480 |
News Archive
CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of California Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184663965 PECOS PAC ID: 8426062027 Enrollment ID: O20060202000956 |
News Archive
CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mohsen Ebneshahidi, MD 3400 Data Dr, Rancho Cordova, CA 95670-7956 Ph: () - | Mohsen Ebneshahidi, MD 18460 Roscoe Blvd Fl 3, Northridge, CA 91325-4107 Ph: (818) 885-5480 |
News Archive
CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.
› Verified 5 days ago
Dr. Prathima Smruthi Charugundla, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 18460 Roscoe Blvd Fl 3, Northridge, CA 91325 Phone: 548-081-8885 Fax: 818-993-1917 | |
Amber Kristy Williams, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 18460 Roscoe Blvd Fl 3, Northridge, CA 91325 Phone: 818-885-5480 Fax: 818-993-1917 | |
Shadi Sharif, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 18460 Roscoe Blvd Fl 3, Northridge, CA 91325 Phone: 818-885-5480 Fax: 818-993-1917 | |
Dr. Sandeep Chadha, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 18460 Roscoe Blvd Fl 3, Northridge, CA 91325 Phone: 818-885-5480 Fax: 818-993-1917 | |
Michael E Damavandi, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 18460 Roscoe Blvd Fl 3, Northridge, CA 91325 Phone: 818-885-5480 Fax: 818-993-1917 | |
Marta Beth Almli, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 18460 Roscoe Blvd Fl 3, Northridge, CA 91325 Phone: 818-885-5480 Fax: 818-993-1917 | |
Dr. Lesley Prince, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 18460 Roscoe Blvd Fl 3, Northridge, CA 91325 Phone: 818-885-5480 Fax: 818-993-1917 |